Processa Pharmaceuticals, Inc.PCSA

Processa Pharmaceuticals’ latest 10-Q shows the company burning $3.6 million in operating cash during the quarter while its cash pile shrank to $1.7 million-enough to cover roughly six weeks of current liabilities and no meaningful cushion for the $11.2 million of future services it still owes under existing contracts. The headline “patient-friendly pipeline” can’t paper over a balance sheet that speaks in terms of red ink and dwindling runway. (source: Processa Pharmaceuticals Inc. 10-Q for the quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1533743/000149315226021721/form10-q.htm)

What Processa actually does is develop small-molecule drugs aimed at life-threatening and life-compromising chronic diseases, with a current focus on PCS11T, a targeted alternative to irinotecan slated for colorectal, small-cell lung and pancreatic cancers. The product page promises a “patient-friendly” profile, but the SEC filings offer no revenue, no approvals, and no imminent cash inflow to pay the bills. Instead, the company points to a history of more than 100 meetings with the FDA and involvement in more than 50 drug-development programmes-credentials that sound impressive until you notice they haven’t yet produced a marketed drug or a profitable quarter. (source: Processa Pharmaceuticals product pipeline page, https://www.processapharmaceuticals.com/product-pipeline)

By 31 March 2026 Processa reported total assets of $4.5 million, liabilities of $2.0 million and shareholders’ equity of $2.5 million, while net income attributable to the parent was a loss of $3.4 million. Diluted earnings per share came in at $-1.29 on 2.6 million diluted shares, and operating cash flow was $-3.6 million for the quarter. The company’s current assets were $3.4 million, of which cash and cash equivalents were $1.7 million, leaving little slack for the $11.2 million of future services it remains contractually obligated to pay. (source: Processa Pharmaceuticals Inc. 10-Q for the quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1533743/000149315226021721/form10-q.htm)

If you want to see where Processa’s share price has been, the company’s own filings won’t tell you; EDGAR offers no price history, no volume data and no liquidity metrics. The only official market artefact is the issuer’s regulatory disclosures-use TradingView or your broker’s charting feed for price action, but recognise that the numbers on those candles come from venues and liquidity pools outside the issuer’s control. (source: Processa Pharmaceuticals Inc. SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1533743)

Processa’s April 30 2026 8-K announced a transition in the employment status of Dr David Young, but the filing stops short of explaining what that means for day-to-day operations, clinical timelines or cash burn. The same document reveals the company is defending a breach-of-contract claim that could add further liabilities, yet provides no quantified estimate of potential exposure. Until the next 10-Q, the source requires readers to take comfort-or discomfort-from silence. (source: Processa Pharmaceuticals Inc. 8-K filed 2026-04-30, https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/form8-k.htm)

What remains unproven is any revenue from marketed products, any regulatory approvals for PCS11T, and any concrete plan to fund the $11.2 million of future services without further dilution. Processa’s track record is heavy on FDA meetings and light on filings that show cash in the bank; the next 10-Q, expected in early November 2026, will tell us whether the company can translate its slideware into actual revenue before the runway disappears. (source: Processa Pharmaceuticals Inc. SEC EDGAR 10-K dated 2026-03-18, https://www.sec.gov/Archives/edgar/data/1533743/000149315226011204/form10-k.htm)